

IGCS 2024 Abstracts:

Regular Submission Short Oral Presentations (IGCS Poster Talk Sessions)

Short oral abstract presentations are included in the below sessions. The sessions will be recorded for on-demand viewing via the IGCS 360 Educational Portal.

IGCS POSTER TALKS 01

Wednesday, October 16, 2:00 – 3:15 PM | The Liffey B

IGCS POSTER TALKS 02

Friday, October 18, 2:30 – 3:30 PM | The Liffey B



PT001 / #646

IGCS POSTER TALKS 01

Topic: AS03. Cervical Cancer

POSTOPERATIVE CHEMOTHERAPY FOR EARLY-STAGE, INTERMEDIATE-RISK CERVICAL CANCER NOT MEETING SEDLIS CRITERIA: A PRELIMINARY ANALYSIS OF A RANDOMIZED CONTROLLED CLINICAL TRIAL

Jing Chen¹, Yingjie Hu¹, Kezhen Li¹, Yaxia Chen², Kun Song³, Ding Ma¹ ¹Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department Of Obstetrics And Gynecology, Wuhan, China, ²Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China, ³Qilu Hospital of Shandong University, Jinan, China


Introduction: There is debate regarding the necessity of adjuvant therapy in early-stage cervical cancer with intermediate-risk factors that do not meet the Sedlis criteria. This study aimed to assess the efficacy of postoperative adjuvant chemotherapy for these patients.

Methods: This trial involving patients with stage IB1, IB2, and IIA1 cervical cancer who had postoperative risk factors not meeting the Sedlis criteria but included invasion depth ≥2/3, moderate to poorly differentiated tumors, lymph-vascular space invasion, adenocarcinoma or adenosquamous carcinoma, or tumor size ≥2cm. Patients were randomly assigned to receive postoperative adjuvant chemotherapy or undergo follow-up observation. The primary endpoint was disease-free survival (DFS).

Results: From January 7th, 2021, to February 29th, 2024, 288 patients underwent randomization, of whom 274 (135 patients in the adjuvant chemotherapy group and 139 patients in the follow-up group) were included in this preliminary analysis, with a median follow-up time of 16 months (IQR: 6-24). Details of risk factors in both groups are presented in Table 1. Three DFS events occurred in the adjuvant chemotherapy group, and 6 events occurred in the follow-up group. The corresponding one-year DFS rates were 98.3% (95% CI: 96.0-100) and 97.2% (95% CI: 94.1-100), respectively (unadjusted HR for adjuvant chemotherapy was 0.53 [95% CI: 0.13-2.10], Fig 1; HR adjusting for stage and tumor size was 0.45 [95% CI: 0.11-1.88]). One death occurred in the adjuvant chemotherapy group.



	Adjuvant chemotherapy group (n=135)	Follow-up group (n=139)	p-value
FIGO Stage			0.001
IB1	63 (46.67)	92 (66.19)	
IB2	37 (27.41)	33 (23.74)	
IIA1	35 (25.93)	14 (10.07)	
Histologic subtype			0.754
SCC	112 (82.96)	113 (81.29)	
AC or ASC	23 (17.04)	26 (18.71)	
Differentiation grade			0.334
G1	3 (2.22)	6 (4.32)	
G2-G3	127 (94.07)	123 (88.49)	
Not reported	5 (3.70)	10 (7.19)	
Tumor Size			0.112
< 2cm	71 (52.59)	87 (62.59)	
≥2cm	64 (47.41)	52 (37.41)	
Depth of invasion			0.009
< 2/3	99 (73.33)	120 (86.33)	
≥2/3	35 (25.93)	18 (12.95)	
Not reported	1 (0.74)	1 (0.72)	
LVSI		988 N.C.	0.424
Yes	26 (19.26)	21 (15.11)	
No	109 (80.74)	118 (84.89)	





Conclusion/Implications: Our short-term analysis did not demonstrate the benefit of postoperative adjuvant chemotherapy for intermediate-risk cervical cancer not meeting Sedlis criteria. Further follow-up is needed to ascertain the findings.



PT002 / #568

IGCS POSTER TALKS 01

Topic: AS03. Cervical Cancer

CADONILIMAB IN COMBINATION WITH DISITAMAB VEDOTIN OR NAB-PACLITAXEL IN THE TREATMENT OF RECURRENT OR METASTATIC CERVICAL CANCER: A PROSPECTIVE, DOUBLE-COHORT, MULTI-CENTER, OPEN-LABEL, PHASE II CLINICAL STUDY (AK001)

Haifeng Gu¹, Jian Zhou¹, Jianwei Wang¹, Lili Liu¹, Yun Zhou¹, Baoyue Pan¹, Weijun Ye¹, Li Zhou², Yan Ding³, Jinxin Bei¹, Xinping Cao¹, <u>Min Zheng⁴</u>


¹Sun Yat-sen University Cancer Center, Guangzhou, China, ²cancer hospital of shantou university medical college, shantou, China, ³Gansu Provincial Cancer Hospital, Lanzhou, China, ⁴Sun Yat-sen University Cancer Center, Gynecology, Guangzhou, China

Introduction: Introduction: The aim of AK001 trial (ChiCTR2300076740) is to investigate the efficacy of cadonilimab in combination with disitamab vedotin or nab-paclitaxel in the treatment of recurrent or metastatic cervical cancer. Here, we report the preliminary results of AK001.

Methods: Patients with recurrent or metastatic cervical cancer who had progressed after 1-3 lines of chemotherapy were eligible in this study. The included patients were divided into two independent cohorts according to the HER2 immunohistochemistry (IHC) expression: cohort I with a HER2 IHC 1+~3+ and cohort II with HER2 0. Patients in Cohort I were treated with cadonilimab and disitamab vedotin biweekly while those in cohort II were treated with cadonilimab and nab-paclitaxel triweekly. The primary endpoint of the study was objective response rate (ORR). A Simon 2-stage design was



utilized.(see Chart 1)



Results: Presently 17 patients have been enrolled in this study including 10 evaluable patients (4 in cohort I and 6 in cohort II), the median follow-up was 4.1 (95%CI 3.2-5.2) months. Baseline characteristics were shown in table 1. For cohort I, the ORR and DCR were 50% (2/4) and 75% (3/4). For cohort II, the ORR and DCR were 66.7%(4/6) and 88.3% (5/6). Toxicity was tolerable in both cohorts.

	Cohort I	Cohort II
Age		
<60	1	4
≥60	3	2
Histologic type		
squamous cell carcinoma	1	6
adenocarcinoma	1	0
other	2	0
Prior lines of systemic therapy		
1	1	5
2~3	3	1
Prior immunotherapy		
Yes	2	2
No	2	4
HER2 expression		
1+	3	0
2+	1	0
3+	0	0

Table 1.Baseline characteristics



Conclusion/Implications: Our preliminary results provide an encouraging solution for the second-line treatment of recurrent or metastatic cervical cancer based on HER2 expression. Cadonilimab plus disitamab vedotin may emerge as a novel effective combination for the treatment of HER2 positive cervical cancer in the future. Data will be updated further.



PT003 / #255

IGCS POSTER TALKS 01

Topic: AS16. Rare Tumors

CLINICAL OUTCOMES WITH TRASTUZUMAB EMTANSINE OR IPATASERTIB PLUS PACLITAXEL FOR PERSISTENT/RECURRENT RARE EPITHELIAL OVARIAN CARCINOMAS: ENGOT-GYN2/GOG-3051/BOUQUET PHASE 2 BIOMARKER-DIRECTED STUDY

David Gershenson¹, Andrés Redondo², Thibault De La Motte Rouge³, Rowan Miller⁴, David O'malley⁵, Sandro Pignata⁶, Ali Ayhan⁷, Philipp Harter⁸, Intidhar Labidi-Galy⁹, Beatriz Pardo¹⁰, Elsa Kalbacher¹¹, Jae-Weon Kim¹², Charlie Gourley¹³, Robert Coleman¹⁴, Luis Manuel Manso Sanchez¹⁵, Dominique Berton¹⁶, Yong Man Kim¹⁷, Anais Malpica¹⁸, Lauren Yauch¹⁹, Max Dieterich²⁰, Ophélie Caras-Zeroug²¹, Venkatesh Krishnan²², Jung-Yun Lee²³, Jubilee Brown²⁴, Isabelle Ray-Coquard²⁵ ¹The University of Texas MD Anderson Cancer Center, Gog-f And Department Of Gynecologic Oncology And Reproductive Medicine, Houston, United States of America, ²Hospital Universitario La Paz-IdiPAZ, Geico And Medical Oncology Department, Madrid, Spain, ³GINECO and Centre Eugène Marquis, Rennes, France, ⁴University College Hospital, Ncri And University College London Hospitals Nhs Foundation Trust, London, United Kingdom, ⁵The Ohio State University and the James CCC, Gog-f And, Columbus, United States of America, ⁶Istituto Nazionale Tumori (IRCCS), Fondazione G. Pascale, Mito And Urology And Gynecology Department, Napoli, Italy, ⁷Baskent University Hospital, Trsgo And Department Of Obstetrics And Gynecology, Ankara, Turkey, ⁸Evang, Kliniken Essen-Mitte, Ago And Department Of Gynaecology & Gynaecologic Oncology, Essen, Germany, ⁹Hôpitaux Universitaires de Genève, Swiss Go And, Geneva, Switzerland, ¹⁰Hospital Duran i Reynals, IDIBELL, L'Hospitalet de LLobregat, Geico And Institut Català D'oncologia,, Barcelona, Spain, ¹¹CHRU Jean Minjoz, Gineco And, Besancon, France, ¹²Seoul National University College of Medicine, Department Of Obstetrics And Gynecology, Seoul, Korea, Republic of, ¹³Cancer Research UK Scotland Centre, University of Edinburgh, Ncri And Nicola Murray Centre For Ovarian Cancer Research, Edinburgh, United Kingdom, ¹⁴The US Oncology Network, Gog-f And Gynecologic Oncology Department, The Woodlands, United States of America, ¹⁵Hospital Universitario 12 de Octubre, Geico And, Madrid, Spain, ¹⁶ICO – Site René Gauducheau, Gineco And, St Herblain, France, ¹⁷Asan Medical Center, Department Of Obstetrics And Gynecology, Seoul, Korea, Republic of, ¹⁸The University of Texas MD Anderson Cancer Center, Gog-f And Department Of Pathology, Houston, United States of America, ¹⁹Genentech, Product Development Oncology, South San Francisco, United States of America, ²⁰F. Hoffmann-La Roche Ltd, Product Development Oncology, Basel, Switzerland, ²¹Cytel Inc – Clinical Research Services, Biostatistics, Geneva, Switzerland, ²²Genentech, Oncology Biomarker Development,



South San Francisco, United States of America, ²³Yonsei University College of Medicine, Gynecologic Cancer Center, Seoul, Korea, Republic of, ²⁴Atrium Health Wake Forest University, Gog-f And Division Of Gynecologic Oncology, Charlotte, United States of America, ²⁵Centre Léon Bérard and University of Lyon, Gineco And Medical Oncology Department, Lyon, France

Introduction: The BOUQUET study (NCT04931342) is evaluating biomarker-directed regimens for rare epithelial ovarian carcinomas (OCs). We report results for trastuzumab emtansine (T-DM1) and ipatasertib+paclitaxel.

Methods: Eligible patients had measurable persistent/recurrent platinum-resistant non-high-grade serous/non-high-grade endometrioid OC confirmed by central pathology review and had received 1–4 prior lines of non-hormonal systemic therapy. Tumour samples were tested centrally (FoundationOne CDx NGS assay). Patients with *ERBB2* amplification and/or mutation received T-DM1 3.6 mg/kg IV day 1 q21d. Patients with *PTEN/PIK3CA/AKT1* alterations received oral ipatasertib 400 mg/day days 1–21 plus IV paclitaxel 80 mg/m² days 1, 8 and 15 q28d. The primary endpoint was investigator-assessed confirmed objective response rate (cORR) per RECIST v1.1.


Results: Among 21 patients treated with T-DM1 (11 clear cell [CC], 8 mucinous, 2 lowgrade serous OC; 18 *ERBB2* amplifications, 3 *ERBB2* mutations), 1 with *ERBB2*amplified CC OC had a partial response (5% cORR). By the data cut-off, 2 patients (both with *ERBB2*-amplified mucinous OC) remained on treatment and 13 had died. In the ipatasertib+paclitaxel arm (n=20), the cORR was 25% (3/17 with CC OC, 2/3 with lowgrade endometrioid OC; 3 *PIK3CA* alteration, 1 *PTEN* alteration, 1 both). By the data cutoff, 1 patient remained on ipatasertib+paclitaxel and 11 had died. Two complete responses were ongoing after >20 months' treatment. There were no treatment-related deaths with either regimen. The table and figure provide further efficacy and safety results.



Parameter	T-DM1 (n=21)	Ipatasertib+paclitaxel (n=20)	
Data cut-off date	25 Nov 2023	15 Jan 2024	
Median follow-up, months (range)	5.3 (0-15)	6.8 (1-22)	
cORR, n (%) [95% CI]	1 (5) [0-24]	5 (25) [9-49]	
Complete response, n (%)	Ô	2 (10)	
Partial response, n (%)	1 (5)	3 (15)	
Median duration of response, months (range)	9.1	9.3 (4-18ª)	
Disease control rate, n (%) [95% CI] ^b	7 (33) [15–57]	7 (35) [15–59]	
6-month PFS rate, % [95% CI]	23 [4-42]	41 [18-65]	
Median PFS, months [95% CI]	2.8 [2.0-4.7]	3.9 [1.7-8.2]	
Median treatment duration, months (range)	2.1 (0–11)	Ipatasertib: 3.0 (0-21) Paclitaxel: 2.7 (0-21)	
Adverse events, n (%)		- 52 - 551.c	
Grade 3/4	10 (48)	17 (85)	
Leading to treatment interruption	7 (33)	Ipatasertib: 12 (60) Paclitaxel: 13 (65)	
Leading to dose reduction	4 (19)	Ipatasertib: 5 (25) Paclitaxel: 5 (25)	
Leading to any treatment discontinuation	0	1 (5)	

^aCensored observation. ^bComplete/partial response or stable disease ≥16 weeks. PES = progression-free survival.





Conclusion/Implications: Minimal clinical activity was observed with T-DM1 in *ERBB2*amplified or -mutated tumours. Ipatasertib+paclitaxel demonstrated more encouraging activity. The tolerability of both regimens was consistent with previous experience.



PT004 / #583

IGCS POSTER TALKS 01

Topic: AS10. Ovarian Cancer

SUCCESSFUL CARBOPLATIN DESENSITIZATION PROTOCOL IN PATIENTS WITH PROVEN OR INCREASED RISK OF CARBOPLATIN HYPERSENSITIVITY REACTION


Mariateresa Lapresa¹, Giuseppe Caruso¹, Gabriella Parma¹, Camilla Ottomano², Costantino Jemos³, Martina Milani⁴, Silvia Derio¹, Marta Mongillo¹, Sara Gandini⁵, Emanuela Omodeo Salè², Nicoletta Colombo¹ ¹IEO European Institute of Oncology IRCCS, Division Of Gynecologic Oncology, Milan, Italy, ²IEO European Institute of Oncology IRCCS, Division Of Pharmacy, Milan, Italy, ³UOC Farmacia Ospedaliera ASST NORD Milano, Sesto San Giovanni, Italy, ⁴ASST Grande Ospedale Metropolitano Niguarda, Farmacologia Clinica, Milan, Italy, ⁵IEO, European Institute of Oncology IRCCS, Department Of Experimental Oncology, Milano, Italy

Introduction: Carboplatin-based chemotherapy remains a cornerstone of treatment for patients with gynecologic cancers; however, hypersensitivity reactions occur in 12-33% of patients retreated with carboplatin. We aimed to assess the efficacy of a carboplatin desensitization protocol to manage patients with proven or increased risk of carboplatin hypersensitivity reactions.

Methods: Patients with gynecologic cancer who underwent a carboplatin desensitization protocol at the European Institute of Oncology (Milan, Italy) between 2014 and 2021 were identified. Patients with a documented hypersensitivity reaction to carboplatin or with a positive skin test before receiving ≥cycle 7 of carboplatin-based therapy were triaged to carboplatin desensitization after steroid premedication (Figure 1 and Figure 2). Descriptive statistics were used to assess the negative predictive value of carboplatin skin test and the number of successful carboplatin infusions.

Results: A total of 621 patients with a mean age of 57 years were included: 469 (76%) ovarian cancer, 87 (14%) endometrial cancer, and 65 (10%) cervical cancer. The number of positive skin tests was 4%, with a higher rate (14%) between the 8th-9th cycles. The negative predictive value of skin testing was 98%. Carboplatin infusion was not initiated in 18% of patients due to severe skin test reactions. A hypersensitivity reaction was reported in 20% of carboplatin desensitization infusions. Reactions were mild in 86% of cases, and the number of completed desensitization infusions was 95%.









Premedication in the 24 hours before carboplatin infusion				
h 2pm	NS 0.9% 100 cc + dexamethasone 12 mg* + PPI 40 mg IV in 30 min			
h 8pm	NS 0.9% 100 cc + dexamethasone 12 mg* + PPI 40 mg + chlorphenamine 10 mg* IV in 30 min			



Standard premedication on the day of carboplatin infusion h 8am NS 0.9% 100 cc + dexamethasone 12 mg* + granisetron 3 mg*+ PPI 40 mg + chlorphenamine 10 mg* IV in 30 min

*Or equivalent.

Carboplatin solution (NS 0.9% or D5W)	Diluition factor	Volume (mL)	Infusion time (min)	Rate (mL/h)	% of total dose infus
lution 1	1:10000	50	15	200	0.01%
Solution 2	1:1000	50	15	200	0.1%
Solution 3	1:100	50	15	200	1%
Solution 4	1:10	50	15	200	10%
NS 0.9% 100 cc + hyd					
Solution 5	1:1	Remainder	180	Variable	88.89%

Abbreviations: D5W, dextrose 5% in water; IV, intravenous; NS, normal saline; PPI, proton-pump inhibitor.

Conclusion/Implications: A 5-step carboplatin desensitization protocol after 24-hour steroid premedication is an effective strategy to complete platinum-based chemotherapy in gynecologic cancer patients with proven or increased risk of carboplatin hypersensitivity reaction.



PT005 / #1267

IGCS POSTER TALKS 01

Topic: AS10. Ovarian Cancer

CASP8 IN OVARIAN CANCER: INSIGHTS ON PARP INHIBITOR RESISTANCE THROUGH MENDELIAN AND SINGLE-CELL ANALYSIS

Xueping Zhu^{1,2,3}, Dongling Zou^{4,5,6,7,8,9}

¹Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China, ²Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China, ³Organoid Transformational Research Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital,, Chongqing, China, ⁴Affiliated Cancer Hospital of Chongqing University, Gynecologic Cancer Center, chongqing, China, ⁵Chongqing university cancer hospital, Chongqing shapingba, China, ⁶Organoid Transformational Research Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, Chongqing, China, ⁷Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, Chongqing shapingba, China, ⁸Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China;, Chongqing, China, ⁹Chongqing University Cancer Hospital, Chongqing, China


Introduction: The causal link between inflammatory proteins and ovarian cancer, particularly in PARP inhibitor (PARPi) resistance, remains elusive.

Methods: We systematically interrogated circulating inflammatory proteins associated with ovarian cancer via Mendelian randomization (MR) analysis. Genetic associations were derived from a large-scale GWAS meta-analysis that enrolled 14,824 predominantly European participants, the Ovarian Cancer National Alliance (OCAC) cohort (25,509 cases and 40,941 controls), and the UK Biobank (1147 cases and 207,089 controls). Colocalization and summary-data-based MR (SMR) analyses validated candidate proteins' causal implication. Single-cell RNA sequencing data from PARPi-resistant and responsive ovarian cancer cohorts were provided by the Cancer Hospital affiliated with Chongqing University. Single cell-type expression analysis, protein-protein interaction (PPI), and druggability evaluation were further conducted to detect the specific cell type with enrichment expression and prioritize potential therapeutic targets. Clinical significance utilized data from The Cancer Genome Atlas (TCGA).




Results: Genetically inferred levels of 5 proteins were associated with ovarian cancer risk. Elevated CD244 and LTA levels, and decreased CST5, CASP8, and CCL25 levels, were linked with heightened ovarian cancer susceptibility. CASP8, notably, were prioritized with the most convincing evidence and correlated robustly with prognosis and disease stage. Diminished CASP8 expression in advanced-stage ovarian cancer indicated poorer clinical outcomes. CASP8 expression was predominant in T/NK cells and epithelial cells within PARPi-resistant ovarian tumor tissues.









Conclusion/Implications: This study underscores CASP8's association with ovarian cancer and PARPi resistance, offering insights into disease etiology and therapeutic avenues for managing ovarian cancer and resistant phenotypes.



PT006 / #314

IGCS POSTER TALKS 01

Topic: AS10. Ovarian Cancer

STEREOTACTIC ABLATIVE RADIOTHERAPY FOR OLIGOMETASTATIC OVARIAN CANCER LYMPH NODE DISEASE: THE MITO-RT3/RAD PHASE II TRIAL

Gabriella Macchia¹, Maura Campitelli², Donato Pezzulla³, Simona Lucci², Andrei Fodor⁴, Donatella Russo⁵, Vittoria Balcet⁶, Paolo Bonome³, Stefano Durante⁷, Lorena Draghini⁸, Francesca Titone⁹, Giuseppe D'Agostino¹⁰, Marinella Tamburo¹¹, Martina Ferioli¹², Edy Ippolito¹³, Francesca Tortoreto¹⁴, Luciana Caravatta¹⁵, Francesca De Felice¹⁶, Aida Di Stefano¹⁷, Mara Fanelli³, Savino Cilla¹⁸, Francesco Cosentino¹⁹, Claudia Marchetti²⁰, Serena Maria Boccia²⁰, Vanda Salutari²⁰, Alessio Morganti²¹, Maria Antonietta Gambacorta², Anna Fagotti²⁰, Sandro Pignata²², Giovanni Scambia²³, Gabriella Ferrandina²⁴, Francesco Deodato³ ¹Università Cattolica del S. Cuore, Gemelli Molise Hospital, Campobasso, Italy, ²3. Fondazione Policlinico Universitario A. Gemelli IRCCS, Unità Operativa Complessa di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italy, ³Responsible Research hospital, Radiation Oncology, Campobasso, Italy, ⁴IRCCS San Raffaele Scientific Institute, Department of Radiation Oncology, Milano, Italy, ⁵Radiotherapy Unit, Ospedale "Vito Fazzi", Lecce, Italy, ⁶Nuovo Ospedale degli Infermi, UOC Radioterapia, Biella, Italy, ⁷IEO European Institute of Oncology IRCCS, Division of radiation oncology, Milano, Italy, 8S Maria Hospital, Radiation Oncology Center, Terni, Italy, ⁹University Hospital Udine, Department of Radiation Oncology, Udine, Italy, ¹⁰Humanitas Clinical and Research Center-IRCCS, Radiotherapy and Radiosurgery Department, Milano, Italy, ¹¹Azienda Ospedaliera "Cannizzaro", UOC di Radioterapia, Catania, Italy, ¹²Azienda USL – IRCCS di Reggio Emilia, Radiation oncology, Reggio Emilia, Italy, ¹³Campus Bio-Medico University, Department of Radiation Oncology, Roma, Italy, ¹⁴Fatebenefratelli Isola Tiberina. Gemelli Isola, UOC di Radioterapia, Roma, Italy, ¹⁵SS Annunziata Hospital, Department of Radiation Oncology, Chieti, Italy, ¹⁶Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Department of Radiotherapy, Roma, Italy, ¹⁷Responsible Research Hospital, Medical Oncology Unit, Campobasso, Italy, ¹⁸Responsible Research hospital, Medical Physics Unit, Campobasso, Italy, ¹⁹Department of Gynecologic Oncology, Responsible Research Hospital and Università degli studi del Molise, Campobasso, Italy, ²⁰UOC Ginecologia Oncologica, Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, ²¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Radiation Oncology, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Radiation Oncology, Bologna, Italy, ²²Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico



(IRCCS), Fondazione G Pascale, 9. Uro-Gynecological Medical Oncology, Napoli, Italy, ²³Policlinico Gemelli, Rome, Italy, ²⁴6. Fondazione Policlinico Universitario A. Gemelli, IRCCS, Unità Operativa Complessa Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Roma, Italy

Introduction: MITO-RT3/RAD(NCT04593381) is a prospective multicenter Phase II trial designed to assess the effectiveness and safety of stereotactic radiotherapy(SBRT) in patients diagnosed with oligometastatic ovarian cancer(oligo-MPR-OC). In this report, we provide the results of the trial in the setting of lymph node disease.

Methods: The primary endpoint was the complete response(CR) rate, secondary endpoints included local control(LC), progression-free survival(PFS), overall survival(OS), treatment-free interval(TFI), and toxicity rates. Sample size was based on a previous study reporting an average 70.0% CR with SBRT. The study was powered to detect an improvement in the CR rate from 70.0% to 85.0%, with an α error of 0.05 (two-sided) and a β error of 0.1.

Results: The study met its primary endpoint of a statistically significant improvement of CR.135 patients with 249 lesions were enrolled across fifteen Institutions from May 2019 to November 2023. CR were observed in 194 lesions(77.9%), PR in 40(16.1%), SD in 14(5.6%), and Progressive Disease(PD) in one lesion(0.4%).The ORR was 94%, with an overall clinical benefit rate of 99.6%. CR lesions exhibited a significantly higher LC rate than partial or not responding lesions(12-month LC: 92.7% vs. 63.1%, p<0.001).The 12-actuarial rates for PFS and for OS were 36.6% and 97.2%, respectively.The 12- actuarial rate for Treatment Free Interval was 52.7%.Twenty-three patients (17.0%) experienced mild acute toxicity. Late toxicity was reported in 9 patients (6.7%), mostly Grade 1.

Conclusion/Implications: This trial confirms the efficacy of ablative SBRT, with minimal toxicity observed. SBRT offered a high CR rate, promising long-term outcomes and systemic-therapy-free survival rate for complete responders.



PT007 / #746

IGCS POSTER TALKS 01

Topic: AS05. Fertility/Pregnancy

THE PROGNOSTIC IMPACT OF MOLECULAR CLASSIFICATION IN ENDOMETRIAL CANCER UNDERGOING FERTILITY-SPARING TREATMENT

Luigi De Vitis^{1,2}, Gabriella Schivardi¹, Anna Viscardi¹, Marina Rosanu¹, Maria Di Giminiani¹, Susanna Delfrati¹, Benedetta Biffi¹, Alessandra Rappa³, Vanna Zanagnolo¹, Giovanni Aletti^{1,4}, Elena Guerini Rocco^{3,4}, Ilaria Betella¹, Fedro Peccatori¹, Dorella Franchi¹, Nicoletta Colombo^{1,5}, Francesco Multinu¹ ¹European Institute of Oncology, Department Of Gynecology, Milan, Italy, ²Mayo Clinic, Department Of Obstetrics And Gynecology, Rochester, United States of America, ³European Institute of Oncology, IEO, IRCCS, Division Of Pathology, Milan, Italy, ⁴University of Milan, Department Of Oncology And Hemato-oncology, Milan, Italy, ⁵University of Milan Bicocca, Faculty Of Medicine And Surgery, Milan, Italy

Introduction: In 2020, 8.6% of endometrial cancer (EC) occurred in women <45 years of age, when fertility preservation is crucial. No biomarkers are available to predict treatment response in EC undergoing fertility-sparing treatment (FST). Therefore, we aimed to evaluate the prognostic role of molecular classification.

Methods: Patients with EC who underwent FST with progestins at the European Institute of Oncology, Milan between 2005-2021 were retrospectively identified. POLE, TP53/p53, mismatch repair (MMR) proteins were assessed to assign patients to a molecular group: POLE mutated (POLEmut), MMR deficient (MMRd), no-specific molecular profile (NSMP), p53 abnormal (p53abn). Treatment response was classified as complete (CR), partial (PR), stable disease (SD), or progressive (PD). Response at 6 months, best response, and recurrence after CR were compared between molecular classes.

Results: Molecular analysis identified 3(9%) POLEmut, 3(9%) MMRd, 25(76%) NSMP, 2(6%) p53abn (Table




Total	POLEmut	MMRd	NSMP	p53abn
33	3	3	25	2
34.8 (31.5, 38.9)	39.2 (30.0, 39.4)	35.6 (33.7, 41.5)	34.3 (31.5, 38.2)	30.2 (22.9, 37.6)
24.8 (22.0, 31.3)	22.8 (22.3, 23.3)	20.8 (19.5, 22.0)	26.7 (22.3, 31.5)	31.3 (31.3, 31.3)
4 (12%)	1 (33%)	1 (33%)	1 (4%)	1 (50%)
10 (45%)	2 (100%)	3 (100%)	5 (31%)	0 (0%)
5 (16%)	0 (0%)	2 (67%)	2 (8%)	1 (50%)
0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
2 (6%)	0 (0%)	0 (0%)	2 (8%)	0 (0%)
8 (25%)	1 (33%)	0 (0%)	7 (29%)	0 (0%)
5 (16%)	0 (0%)	1 (33%)	4 (17%)	0 (0%)
15 (45%)	1 (33%)	1 (33%)	12 (48%)	1 (50%)
10 (30%)	2 (67%)	1 (33%)	6 (24%)	1 (50%)
8 (24%)	0 (0%)	1 (33%)	7 (28%)	0 (0%)
7 (21%)	0 (0%)	0 (0%)	6 (24%)	1 (50%)
1 (3%)	0 (0%)	0 (0%)	1 (4%)	0 (0%)
22 (67%)	3 (100%)	3 (100%)	16 (64%)	0 (0%)
3 (9%)	0 (0%)	0 (0%)	2 (8%)	1 (50%)
23 (70%)	2 (67%)	2 (67%)	18 (72%)	1 (50%)
1 (3%)	0 (0%)	1 (33%)	0 (0%)	0 (0%)
5 (15%)	1 (33%)	0 (0%)	4 (16%)	0 (0%)
4 (12%)	0 (0%)	0 (0%)	3 (12%)	1 (50%)
6 (35W)	1 (50%)	0/08/5	4 (3394)	1 (10092)
				1 (100%)
17 (74%)	1 (50%)	2 (100%)	14 (7676)	0 (0%)
a (3702)	a. (a)()	0.4004	0 (331)	4 (5 840)
				1 (50%)
24 (73%)	3 (100%)	3 (100%)	17 (68%)	1 (50%)
	2.14.0000			
				1 (100%)
				0 (0%)
1 (4%)	0 (0%)	1 (33%)	0 (0%)	0 (0%)
	a 140000			
The second s				2 (100%)
	 34.8 (31.5, 38.9) 24.8 (22.0, 31.3) 4 (12%) 10 (45%) 5 (16%) 0 (0%) 2 (6%) 8 (25%) 5 (16%) 15 (45%) 10 (30%) 8 (24%) 7 (21%) 1 (3%) 22 (67%) 3 (9%) 23 (70%) 1 (3%) 5 (15%) 	34.8 (31.5, 38.9)39.2 (30.0, 39.4)24.8 (22.0, 31.3)22.8 (22.3, 23.3)4 (12%)1 (33%)10 (45%)2 (100%)5 (16%)0 (0%)0 (0%)0 (0%)2 (5%)0 (0%)8 (25%)1 (33%)5 (16%)0 (0%)1 (33%)1 (33%)1 (30%)2 (67%)1 (13%)0 (0%)1 (13%)0 (0%)2 (2 (67%)3 (100%)1 (3%)0 (0%)2 (2 (67%)3 (100%)1 (3%)0 (0%)2 (10%)1 (33%)1 (3%)0 (0%)2 (10%)3 (100%)1 (3%)0 (0%)1 (3%)0 (0%)1 (3%)0 (0%)1 (3%)0 (0%)1 (3%)0 (0%)1 (17)1 (50%)1 (17)1 (50%)1 (17)1 (50%)1 (17)3 (100%)2 (17)0 (0%)1 (14%)0 (0%)1 (14%)0 (0%)	34.8 (31.5, 38.9)39.2 (30.0, 39.4)35.6 (33.7, 41.5)24.8 (22.0, 31.3)22.8 (22.3, 23.3)20.8 (19.5, 22.0)4 (12%)1 (33%)1 (33%)10 (45%)2 (100%)3 (100%)5 (16%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)2 (6%)0 (0%)0 (0%)8 (25%)1 (33%)0 (0%)5 (16%)0 (0%)1 (33%)5 (16%)0 (0%)1 (33%)6 (10,30%)2 (67%)1 (33%)7 (21%)0 (0%)1 (33%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)1 (33%)1 (3%)0 (0%)1 (33%)1 (3%)0 (0%)1 (33%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)0 (0%)1 (3%)0 (0%)0 (0%)1 (17/40%)1 (50%)0 (0%)1 (12%)0 (0%)0 (0%)1 (263%)3 (100%)2 (67%)1 (203%)3 (100%)2 (67%)2 (203%)3 (100%)2 (67%)2 (203%)3 (100%)2 (67%)2 (203%)3 (100%)2 (67%)2 (203%)3 (100%)2 (67%)2 (203%)3 (100%)2 (67%)2 (203	34.8 (31.5, 38.9)39.2 (30.0, 39.4)35.6 (33.7, 41.5)34.3 (31.5, 38.2)24.8 (22.0, 31.3)22.8 (22.3, 23.3)20.8 (19.5, 22.0)26.7 (22.3, 31.5)24.12%)1 (33%)3 (100%)5 (33.%)1 (4%)10.45%)2 (100%)2 (67%)2 (8%)2 (8%)0.0%10.0%10.0%)0 (0%)2 (8%)10.6%)0.0%10.0%)0.0%)2 (8%)2 (6%)0.0%10.0%)1 (33%)2 (8%)2 (6%)0.0%11 (33%)1 (24%)10.10%)0.0%11 (33%)1 (24%)10.10%)2 (67%)1 (33%)6 (24%)10.10%)0.0%11 (33%)6 (24%)10.10%)0.0%11 (33%)6 (24%)11.3%10.0%10.0%11 (4%)11.3%10.0%10.0%11 (4%)11.3%10.0%10.0%11 (4%)11.3%10.0%11 (33%)0 (0%)11.3%10.0%11 (33%)0 (0%)11.3%10.0%11 (33%)0 (0%)11.3%10.0%11 (33%)0 (0%)11.3%10.0%11 (33%)0 (0%)11.3%10.0%11 (33%)1 (3%)11.3%11 (50%)0.0%11 (3%)11.3%11 (50%)0.0%11 (3%)11.3%11 (0%)0.0%11 (3%)11.3%11 (0%)0.0%11 (3%)11.3%11 (3%)0.0%11 (3%)12.10%11 (50%)0.0%11 (3%) <t< td=""></t<>

Table 1. Characteristics of endometrial cancer patients undergoing fertility-sparing treatment according to molecular class

1).

0/3(0%) POLEmut, 0/3(0%) MMRd, 6/25(24%) NSMP, and 1/2(50%) p53abn achieved CR within 6 months. In terms of best response during the entire treatment period, 2/3(67%) POLEmut, 2/3(67%) MMRd, 18/25(72%) NSMP, and 1/2(50%) p53abn showed CR. After achieving CR, 1/2(50%) POLEmut, 2/2(100%) MMRd, 14/18(78%) NSMP, and 0/1(0%) p53abn had a recurrence (Figure 1).





Each bar represents one subject in the study

At the last follow-up, 1/25(4%) NSMP was alive with disease, all others showed no evidence of disease.

Conclusion/Implications: Most EC undergoing FST were NSMP. Although the low number of patients limits our findings, MMRd showed a poorer response to progestins compared to NSMP (0 vs. 24% CR at 6 months and 100 vs. 78% relapsed after CR), similar to previous studies.



PT008 / #908

IGCS POSTER TALKS 02

Topic: AS20. Survivorship

THE MENOPAUSE AFTER CANCER (MAC) STUDY – MULTIMODAL, TECHNOLOGY-ASSISTED INTERVENTION FOR THE MANAGEMENT OF MENOPAUSE AFTER CANCER IMPROVES INSOMNIA SYMPTOMS

Fionan Donohoe¹, <u>Teresa Treacy</u>¹, Aidin Roberts¹, Helen Ryan^{1,2}, Yvonne O'meara¹, Donal Brennan³

¹Living Well Cancer Programme, Gynaecological Oncology, Dublin, Ireland, ²Mater Misericordiae University Hospital, Gynaecological Oncology Department, Dublin, Ireland, ³UCD Gynaecological Oncology Group, Ucd School Of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland

Introduction: Sleep disturbance is commonly experienced by cancer survivors, with rates ranging from 25-59%. Often this can be due to vasomotor symptoms (VMS), particularly in women who are ineligible for menopause hormonal therapy.

Methods: The MAC Study ((NCT04766229) was a prospective, single arm, phase 2 trial examining the impact of a composite intervention consisting of -Non-hormonal pharmacotherapy to manage VMS -Digital CBT for insomnia (dCBT-I) through Sleepio (BigHealth) -Self-management strategies for VMS, -Nominated support person. The trial met its primary endpoint, improvement cancer-specific global quality of life (QOL), here we present data on sleep outcomes as a secondary end point.

Results: 204 women (82% history of breast cancer). were recruited, with a median age of 49, (range 28 – 66). 93% met diagnosis criteria for insomnia (SCI<16) at baseline, which reduced to 45.2% at 6 months (p<0.001). The mean SCI score increased from 8.5 (SEM 0.4) to 17.3 (SEM0.5) at 6 months (p<0.0005). Clinically relevant changes were seen in sleep parameters, with sleep onset latency reducing by 13.6 minutes after completion of dCBT-I (p<0.001). A 35 minute reduction in wakefulness after sleep onset was also seen (p<0.001) alongside a 29.1% improvement in sleep quality (p<0.001). Comparison of breast cancer and non-breast cancer patients demonstrated the intervention was equally effective in both groups.

Conclusion/Implications: The MAC study demonstrated that a targeted composite intervention can improve sleep and self-reported insomnia symptoms for women with troublesome VMS after a cancer diagnosis, which contributed to an improvement in cancer specific global QOL.



PT009 / #845

IGCS POSTER TALKS 02

Topic: AS19. Surgical Techniques and Perioperative Management

SHORT TERM V/S EXTENDED COURSE OF LMWH FOLLOWING MAJOR GYNECOLOGICAL SURGERIES : A RANDOMIZED CONTROLLED TRIAL.

<u>Garima Yadav</u>, Pratibha Singh, Meenakshi Gothwal, Shashank Shekhar, Aieman Sani AIIMS, Jodhpur, India

Introduction: Incidence of post-operative venous thromboembolism (VTE), in the absence of any prophylaxis, in patients undergoing gynecological surgeries is 15-40%. The guidelines for VTE prophylaxis recommend the use of LMWH for 28 days in women undergoing gynecologic oncological surgery, but, these recommendations have not been clearly validated. The primary objective of this study was to assess the incidence of VTE in high risk women, receiving seven v/s twenty-eight-day LMWH for thromboprophylaxis and secondary objective was to compare the incidence of major bleeding episodes following 3 months of surgery.

Methods: It was a Randomized Controlled trial including patients undergoing major gynecological surgeries and at high risk of VTE (Caprini score \geq 4). The patients were randomized into short course (7 days) and extended course (28 days) of post-operative LMWH therapy. The incidence of VTE and bleeding complications was assessed in both groups at the end of three month follow up.

Results: A total of 256 women were assessed, 134 of them received short course of LMWH while 122 received long course. There was no VTE event in the short-course group while one patient had pulmonary embolism on day 4 of surgery in the long arm group. There was no incidence of any major bleeding episode in both the groups while the incidence of minor bleeding episodes was significantly higher in the long-course group (6.7% v/s 17.2%).

Conclusion/Implications: The study concludes that the post-operative use of short course LMWH is as effective as long-course thromboprophylaxis in preventing VTE and its sequelae.



PT010 / #827

IGCS POSTER TALKS 02

Topic: AS04. Endometrial/Uterine Corpus Cancers

DNA DAMAGE RESPONSE ALTERATIONS WITHIN MOLECULAR SUBGROUPS OF ENDOMETRIAL CANCER AND ASSOCIATION WITH PLATINUM CHEMOTHERAPY RESPONSE: AN ENDOMETRIAL CANCER MOLECULARLY TARGETED THERAPY CONSORTIUM STUDY

Barbara Blachut¹, Premal Thaker¹, Matthew Powell², Carson Smitherman³, Angeles Alvarez Secord⁴, <u>Christina Washington⁵</u>, Kathleen Moore⁶, Paulina Haight⁵, Casey Cosgrove⁷, Sarah Crafton⁸, Bhavana Pothuri⁹, Margaret Klein¹⁰, Victoria Bae-Jump¹¹, Dana Chase¹², Stephanie Gaillard¹³, Jason Wright¹⁴, Amanda Jackson¹⁵, Emily Ko¹⁶, Bradley Corr¹⁷, Allison Puechl¹⁸, Gottfried Konecny¹², Linda Duska¹⁹, Tara Castellano¹⁰, Peter Ketch²⁰, Michael Toboni²⁰, Kari Hacker⁹, Peinan Zhao²¹, Mary Mullen²¹ ¹Washington University School of Medicine and Siteman Cancer Center in St. Louis, St. Louis, United States of America, ²National Cancer Institute-sponsored NRG Oncology, Washington University School of Medicine, St Louis, United States of America, ³Duke Cancer Institute, Duke University Medical Center, Durham, NC, Durham, United States of America, ⁴Duke Cancer Institute, Durham, United States of America, ⁵University of Oklahoma Health Sciences, Oklahoma City, United States of America, 6Stephenson Cancer Center, Gynecologic Oncology, Oklahoma city, United States of America, ⁷The Ohio State University Comprehensive Cancer Center, Columbus, United States of America, ⁸Allegheny Health Network, Pittsburgh, United States of America, ⁹NYU Langone Health, Obstetrics And Gynecology, New York, United States of America, ¹⁰Louisiana State University School of Medicine, Louisiana, United States of America, ¹¹University of North Carolina, Department Of Obstetrics And Gynecology, Chapel Hill, United States of America, ¹²University of California, Los Angeles, Los Angeles, United States of America, ¹³Johns Hopkins, Baltimore, United States of America, ¹⁴Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, United States of America, ¹⁵University of Cincinnati, Cincinnati, United States of America, ¹⁶Penn Medicine, Philadelphia, United States of America, ¹⁷University of Colorado, Obstetrics & Gynecology, Aurora, United States of America, ¹⁸Atrium Health Carolinas Medical Center, Charlotte, United States of America, ¹⁹UVA School of Medicine, Charlottesville, United States of America, ²⁰University of Alabama at Birmingham, Birmingham, United States of America, ²¹Washington University School of Medicine, St. Louis, United States of America



Introduction: To describe alterations in DNA damage response (DDR) genes within distinct molecular subtypes of endometrial cancer and to evaluate the relationship between DDR gene mutations, platinum chemotherapy response, and overall survival.

Methods: Data was extracted from the national Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium. Next-generation sequencing and molecular profiling was used to define molecular subtypes and DDR alterations. The association between DDR gene mutations and platinum sensitivity (defined as partial or complete response) and survival was analyzed using Kaplan-Meier curves and risk estimates.

Results: 769 patient tumors across 14 institutions were analyzed (Table 1). The most common DDR gene mutations were *ARID1A*, *ATM*, *BRCA2*,

and *BRCA1*. *ARID1A* mutations were higher in POLE-mutated, MMR-D, and p53wt than p53mut tumors (*P*<0.001). In p53wt tumors, *BRCA1* mutation was predictive of platinum chemotherapy sensitivity (RR=1.71, *P*=0.001). In p53wt tumors, *AKT* mutation was predictive of improved overall survival (median OS months 20.9 vs. 32.7 *P*=0.004.).

Table 1. Most common DDR Mutations within endometrial cancer molecular subgroups.

	All (n=769)	POLE- mutated (n=18)	MMR-D (n=157)	p53wt (n=351)	p53abn (n=243)
ARID1A (%)	34.9	76.5	86.1	8.7	45.9
ATM (%)	6.6	29.4	13.8	1.8	8.3
BRCA1 (%)	4.0	5.9	8.2	2.2	4.6
BRCA2 (%)	5.7	17.7	14.4	3.0	6.6
CHD4 (%)	2.4	0	4.5	0.9	2.8
RAD51 (%)	2.3	0	1.5	4.5	1.4
TMB-High (%)	16.8	66.7	67.0	0	2.5

Conclusion/Implications: The rates of DDR alterations adiffers amongst endometrial cancer molecular subgroups and are associated with platinum chemotherapy response and survival. Our findings provide a foundation for precision medicine in endometrial cancer.



PT011 / #872

IGCS POSTER TALKS 02

Topic: AS04. Endometrial/Uterine Corpus Cancers

LAPAROSCOPIC OR LAPAROTOMIC SURGICAL APPROACH IN ENDOMETRIAL CARCINOMA IS STILL A MATTER OF DEBATE? RESULTS FROM THE TOTEM RANDOMIZED TRIAL.

<u>Annamaria Ferrero</u>¹, Anna Castiglione², Elisa Piovano³, Eva Pagano², Luca Fuso¹, Luca Pace¹, Giovannino Ciccone², Paolo Zola⁴

¹SCDU Ginecologia e Ostetricia - AO Ordine Mauriziano Torino, Dipartimento Di Scienze Chirurgiche - Università Degli Studi Di Torino, Torino, Italy, ²SSD Epidemiologia Clinica e Valutativa, Aou Città Della Salute E Della Scienza Di Torino E Cpo Piemonte, Torino, Italy, ³SCDU Ginecologia e Ostetricia 2U - Ospedale Sant'Anna, Aou Città Della Salute E Della Scienza Di Torino, Torino, Italy, ⁴Dipartimento di Scienze Chirurgiche, Università degli studi di Torino, Torino, Italy

Introduction: Laparoscopic approach (LPS) is recommended by the ESGO/ESTRO/ESP guidelines over laparotomic surgery (LPT) for the treatment of endometrial carcinoma (EC), even if there is still interest in comparing long term overall survival (OS), especially in high-risk patients. The large and pragmatic TOTEM trial, designed to compare intensive versus minimalist follow-up after surgery for EC, was analyzed to evaluate the impact of LPS vs LPT approaches on OS.

Methods: We included all randomized patients with complete surgical data. The association between surgical approach and OS was estimated with Cox models adjusted for age, risk class, histology, adjuvant therapy, follow-up type and stratified by center. Moreover, we evaluated if LPS effect was different according to risk class adding an interaction term.

Results: Out of 1840 patients, 926 underwent LPS (50.3%). The two groups (LPS and LPT) were well balanced by age, histology, and type of follow-up. In the LPS group, a lower proportion of patients were at high risk (32.1% vs 47.5%) and received an adjuvant treatment (25.4% vs 41.1%). Overall, we did not observe a clear difference between LPS vs LPT in terms of OS (HR=0.85 95%CI [0.60,1.20], p=0.352). Moreover, we observed a similar LPS effect in low-risk (HR=0.99; 95%CI=0.60-1.62 p=0.956) and in high risk patients (HR=0.76; 95%CI=0.49-1.18 p=0.224) (p for interaction=0.400).

Conclusion/Implications: A secondary analysis of the TOTEM trial confirmed that OS was very similar between LPS and LPT approaches for EC surgery, both in low and high-risk patients. On behalf of TOTEM Collaborative Group.



PT012 / #560

IGCS POSTER TALKS 02

Topic: AS03. Cervical Cancer

ASSOCIATION OF SURGICAL APPROACH WITH ONCOLOGIC OUTCOMES IN LOW-RISK CERVICAL CANCER: POPULATION BASED COHORT STUDY

Maria Cusimano¹, Amanda Poxon², Lilian Gien³, Rinku Sutradhar⁴, Lena Nguyen⁴, Emily Van De Laar⁵, Ning Liu⁴, Vanessa Ballin⁵, Megan Watts⁵, Marie Plante⁶, <u>Sarah Ferguson⁵</u> ¹Lahey Hospital & Medical Center, Gynecology, Burlington, United States of America, ²University of Toronto, Toronto, Canada, ³University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Canada, ⁴ICES, Toronto, Canada, ⁵Princess Margaret Cancer Centre, Gynecologic Oncology, Toronto, Canada, ⁶Centre Hospitalier Universitaire de Québec, Département D'obstétrique Et Gynécologie, Quebec City, Canada

Introduction: To determine whether the association between minimally invasive surgery (MIS) and oncologic outcomes varies by cervical cancer risk group.

Methods: We performed a population-based cohort study of all cervical cancer patients undergoing primary radical hysterectomy by a gynecologic oncologist from 2006-2017 in Ontario, Canada. Overlap weighted survival models were used to examine the association between surgical approach and oncologic outcomes, adjusting for clinical and pathological characteristics. We tested for an interaction between surgical approach and disease risk group, with patients classified as low- or high-risk based on CCTG CX.5-SHAPE criteria (low risk: depth of invasion <10mm and maximum tumour diameter ≤20mm).

Results: We identified 903 patients (MIS 450, open 453, low-risk 621, high-risk 282) with median age 44 years (IQR 38-53) and median follow-up 9 years (IQR 6-11). Compared to open surgery, MIS was associated with significantly increased rates of cervical cancer death (HR 3.27, 95% CI 1.29-8.31, p=0.01) but not all-cause death (HR 1.65, 0.90-3.04, p=0.11) or recurrence (HR 1.57, 0.89-2.77, p=0.12). This association varied based on disease risk group: MIS was associated with increased all-cause death in high-risk patients (HR 2.93, 1.22-7.03, p=0.02), but not in low-risk patients (HR 0.83, 0.34-2.06, p=0.69; p-interaction=0.05). Similar patterns were observed for cervical cancer death and recurrence.

Conclusion/Implications: Oncologic outcomes after MIS may vary according to disease risk group. MIS does not appear to be associated with increased all-cause mortality in patients with low-risk disease. Additional studies are required to confirm whether MIS may remain safe in a low-risk population defined by strict SHAPE criteria.